1372-P: Micro and Macro Complications Three-Year Follow-up in LANDMARC—Longitudinal Nationwide Study on Real-World Outcomes of Type 2 Diabetes in India

Microvascular and macrovascular complications were evaluated during the 3 years (yrs) of LANDMARC, a prospective observational study (CTRI/2017/05/008452) that included participants with T2D on ≥2 antihyperglycemic medications. Out of 6222 evaluable participants (mean baseline age: 52.1 yrs, T2D duration: 8.6 yrs and A1C: 8.05%), 5273 participants completed the 3-yr follow-up. The mean A1C decreased by 0.68% (p<0.0001) in 3 yrs. Microvascular complications were noted in 18.02% (1121/6222) of participants, while the incidence of macrovascular complications was 3.29% (205/6222). Neuropathy was the most commonly reported complication (baseline: 11.8% and 3-yrs: 14.8%). The 3-yr results indicate slightly higher complications among those who were overweight, but the difference was non-significant (p=0.8380); and significantly higher complications among those with suboptimal glycemic control (p<0.0001) or having CV risk factors (p<0.0001) (Table). The most common macrovascular complication was MI. A total of 37 CV deaths were reported, with majority being sudden deaths (n=24), followed by fatal myocardial infarction (MI, n=10), coronary artery procedure (n=2), and stroke (n=1). These results offer insights into disease progression and suggest the need for controlling risk factors and timely treatment adjustment in participants with T2D. Disclosure N.Rais: Advisory Panel; Bayer Consumer Care AG, Board Member; Abbott, Biocon. A.Sugumaran: Employee; Sanofi. A.Satpathy: Employee; Sanofi. A.Gadekar: Employee; Sanofi. S.K.Menon: Employee; Sanofi. R.Neogi: Employee; Sanofi. D.Chodankar: Employee; Sanofi. C.Trivedi: None. S.Wangnoo: None. A.H.Zargar: None. K.Kumar: None. A.K.Das: n/a. S.R.Joshi: Advisory Panel; Biocon, Zydus Cadila, Torrent Pharmaceuticals Ltd, Franco India, Consultant; Glenmark Pharmaceuticals, Twin Health, Speaker's Bureau; Abbott Nutrition, Sanofi, Abbott, Novo Nordisk, Lupin Pharmaceuticals, Inc. A.Mithal: Advisory Panel; Eris Lifesciences Ltd., Consultant; Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Inc., USV Private Limited, Research Support; Sanofi, Speaker's Bureau; Novo Nordisk, Boehringer-Ingelheim, AstraZeneca, Sun Pharmaceutical Industries Ltd., Novartis. S.Kalra: Speaker's Bureau; Abbott, Bayer Inc., Novo Nordisk, Sanofi. A.Unnikrishnan: Speaker's Bureau; Sanofi, AstraZeneca, Boehringer-Ingelheim, Intas Pharmaceuticals Ltd. H.Thacker: None. B.Sethi: None. S.Chowdhury: None. Funding Sanofi India